ProCE Banner Activity

Recent Advances in the Management of Gynecologic Cancers: Experts Share Their Thoughts on the Latest Clinical Evidence

Clinical Thought
Read this expert commentary to gain insights into the latest clinical evidence for the management of endometrial, ovarian, and cervical cancer.

Released: August 06, 2021

Expiration: August 05, 2022

No longer available for credit.

Share

Faculty

Robert E. Coleman

Robert E. Coleman, MD, FRCP

Professor and Honorary Consultant Medical Oncologist
Cancer Clinical Trials Centre
Academic Unit of Clinical Oncology
Weston Park Hospital
Sheffield, England

Linda R. Duska

Linda R. Duska, MD, MPH, FACOG, FACS, FASCO

Gynecologic Oncologist
Department of OB GYN/Gynecologic Oncology
University of Virginia School of Medicine
Charlottesville, Virginia

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

GlaxoSmithKline

Faculty Disclosure

Primary Author

Robert E. Coleman, MD, FRCP

Professor and Honorary Consultant Medical Oncologist
Cancer Clinical Trials Centre
Academic Unit of Clinical Oncology
Weston Park Hospital
Sheffield, England

Robert L. Coleman, MD, FACOG, FACS, has disclosed that he has received consulting fees from AbbVie, Agenus, Alkermes, Aravive, AstraZeneca, Clovis, Deciphera, Epsilogen, Genmab, Immunogen, Merck, Novocure, and Roche/Genentech; funds for research support from AbbVie, AstraZeneca, Clovis, Genmab, Immunogen, Merck, and Roche/Genentech; and fees for non–CME/CE services from AstraZeneca.

Linda R. Duska, MD, MPH, FACOG, FACS, FASCO

Gynecologic Oncologist
Department of OB GYN/Gynecologic Oncology
University of Virginia School of Medicine
Charlottesville, Virginia

Linda R. Duska, MD, MPH, has disclosed that she has received consulting fees from Cue Biopharma, Genentech/Roche, and Merck; funds for research support paid to her institution from AbbVie, Aduro, Advaxis, Aeterna Zentaris, Bristol-Myers Squibb, Cerulean, Genentech/Roche, GlaxoSmithKline, Leap, Merck, Ludwig, Millennium, Morab, Morphotek, Novartis, Pfizer, Seagen, Syndax, and Tesaro; and other financial or material support from Inovio.